Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription-polymerase chain reaction for tyrosine hydroxylase mRNA

Yuji Miyajima, Keizo Horibe, Minoru Fukuda, Kimikazu Matsumoto, Shin Ichiro Numata, Hiroshi Mori, Koji Kato

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

BACKGROUND. The aim of this study was to evaluate the changes of tumor cell contamination in bone marrow (BM) and peripheral blood (PB) during the clinical course of patients with advanced neuroblastoma by detecting tyrosine hydroxylase (TH) mRNA to clarify the appropriate source and time for harvesting hematopoietic stem cells for transplantation. METHODS. A total of 15 patients with Stage IV neuroblastoma were studied. All 15 patients had peripheral blood stem cell (PBSC) samples and BM samples examined for TH mRNA by using the reverse transcription-polymerase chain reaction (RT-PCR) at the time of harvest. Nine of the 15 patients, also had BM and PB samples examined sequentially. RESULTS. Comparing the 45 paired samples concurrently drawn, 16 of 28 BM samples (57.1%) and 4 of 28 PB samples (14.2%) obtained during complete remission (CR) were positive for TH mRNA (P < 0.01), whereas 17 of 17 BM samples (100%) and 14 of 17 PB samples (82.3%) obtained before CR was achieved were positive (not significant). The incidence of TH mRNA positivity was significantly lower in the samples obtained during CR than those obtained before CR was achieved (P < 0.0001 for PB samples, P < 0.01 for BM samples). At the time of PBSC harvesting, the incidence of TH mRNA positivity was lower in PBSC samples (3 of 15, 20%) than in BM samples obtained concurrently (10 of 15, 66.7%; P < 0.03). CONCLUSIONS. These findings show that there is a substantial risk of tumor cell contamination in harvested PBSCs, although its incidence was lower than that in BM samples. We recommend that PBSCs would be better harvested during remission and should be examined for tumor contamination before use as a stem cell source.

Original languageEnglish
Pages (from-to)1214-1219
Number of pages6
JournalCancer
Volume77
Issue number6
DOIs
Publication statusPublished - Mar 15 1996
Externally publishedYes

Fingerprint

Tyrosine 3-Monooxygenase
Neuroblastoma
Reverse Transcription
Bone Marrow
Polymerase Chain Reaction
Messenger RNA
Neoplasms
Incidence
Hematopoietic Stem Cell Transplantation
Stem Cells
Peripheral Blood Stem Cells

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription-polymerase chain reaction for tyrosine hydroxylase mRNA. / Miyajima, Yuji; Horibe, Keizo; Fukuda, Minoru; Matsumoto, Kimikazu; Numata, Shin Ichiro; Mori, Hiroshi; Kato, Koji.

In: Cancer, Vol. 77, No. 6, 15.03.1996, p. 1214-1219.

Research output: Contribution to journalArticle

Miyajima, Yuji ; Horibe, Keizo ; Fukuda, Minoru ; Matsumoto, Kimikazu ; Numata, Shin Ichiro ; Mori, Hiroshi ; Kato, Koji. / Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription-polymerase chain reaction for tyrosine hydroxylase mRNA. In: Cancer. 1996 ; Vol. 77, No. 6. pp. 1214-1219.
@article{3b7b49f887b347fbae97d56957ab37b8,
title = "Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription-polymerase chain reaction for tyrosine hydroxylase mRNA",
abstract = "BACKGROUND. The aim of this study was to evaluate the changes of tumor cell contamination in bone marrow (BM) and peripheral blood (PB) during the clinical course of patients with advanced neuroblastoma by detecting tyrosine hydroxylase (TH) mRNA to clarify the appropriate source and time for harvesting hematopoietic stem cells for transplantation. METHODS. A total of 15 patients with Stage IV neuroblastoma were studied. All 15 patients had peripheral blood stem cell (PBSC) samples and BM samples examined for TH mRNA by using the reverse transcription-polymerase chain reaction (RT-PCR) at the time of harvest. Nine of the 15 patients, also had BM and PB samples examined sequentially. RESULTS. Comparing the 45 paired samples concurrently drawn, 16 of 28 BM samples (57.1{\%}) and 4 of 28 PB samples (14.2{\%}) obtained during complete remission (CR) were positive for TH mRNA (P < 0.01), whereas 17 of 17 BM samples (100{\%}) and 14 of 17 PB samples (82.3{\%}) obtained before CR was achieved were positive (not significant). The incidence of TH mRNA positivity was significantly lower in the samples obtained during CR than those obtained before CR was achieved (P < 0.0001 for PB samples, P < 0.01 for BM samples). At the time of PBSC harvesting, the incidence of TH mRNA positivity was lower in PBSC samples (3 of 15, 20{\%}) than in BM samples obtained concurrently (10 of 15, 66.7{\%}; P < 0.03). CONCLUSIONS. These findings show that there is a substantial risk of tumor cell contamination in harvested PBSCs, although its incidence was lower than that in BM samples. We recommend that PBSCs would be better harvested during remission and should be examined for tumor contamination before use as a stem cell source.",
author = "Yuji Miyajima and Keizo Horibe and Minoru Fukuda and Kimikazu Matsumoto and Numata, {Shin Ichiro} and Hiroshi Mori and Koji Kato",
year = "1996",
month = "3",
day = "15",
doi = "10.1002/(SICI)1097-0142(19960315)77:6<1214::AID-CNCR31>3.0.CO;2-2",
language = "English",
volume = "77",
pages = "1214--1219",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription-polymerase chain reaction for tyrosine hydroxylase mRNA

AU - Miyajima, Yuji

AU - Horibe, Keizo

AU - Fukuda, Minoru

AU - Matsumoto, Kimikazu

AU - Numata, Shin Ichiro

AU - Mori, Hiroshi

AU - Kato, Koji

PY - 1996/3/15

Y1 - 1996/3/15

N2 - BACKGROUND. The aim of this study was to evaluate the changes of tumor cell contamination in bone marrow (BM) and peripheral blood (PB) during the clinical course of patients with advanced neuroblastoma by detecting tyrosine hydroxylase (TH) mRNA to clarify the appropriate source and time for harvesting hematopoietic stem cells for transplantation. METHODS. A total of 15 patients with Stage IV neuroblastoma were studied. All 15 patients had peripheral blood stem cell (PBSC) samples and BM samples examined for TH mRNA by using the reverse transcription-polymerase chain reaction (RT-PCR) at the time of harvest. Nine of the 15 patients, also had BM and PB samples examined sequentially. RESULTS. Comparing the 45 paired samples concurrently drawn, 16 of 28 BM samples (57.1%) and 4 of 28 PB samples (14.2%) obtained during complete remission (CR) were positive for TH mRNA (P < 0.01), whereas 17 of 17 BM samples (100%) and 14 of 17 PB samples (82.3%) obtained before CR was achieved were positive (not significant). The incidence of TH mRNA positivity was significantly lower in the samples obtained during CR than those obtained before CR was achieved (P < 0.0001 for PB samples, P < 0.01 for BM samples). At the time of PBSC harvesting, the incidence of TH mRNA positivity was lower in PBSC samples (3 of 15, 20%) than in BM samples obtained concurrently (10 of 15, 66.7%; P < 0.03). CONCLUSIONS. These findings show that there is a substantial risk of tumor cell contamination in harvested PBSCs, although its incidence was lower than that in BM samples. We recommend that PBSCs would be better harvested during remission and should be examined for tumor contamination before use as a stem cell source.

AB - BACKGROUND. The aim of this study was to evaluate the changes of tumor cell contamination in bone marrow (BM) and peripheral blood (PB) during the clinical course of patients with advanced neuroblastoma by detecting tyrosine hydroxylase (TH) mRNA to clarify the appropriate source and time for harvesting hematopoietic stem cells for transplantation. METHODS. A total of 15 patients with Stage IV neuroblastoma were studied. All 15 patients had peripheral blood stem cell (PBSC) samples and BM samples examined for TH mRNA by using the reverse transcription-polymerase chain reaction (RT-PCR) at the time of harvest. Nine of the 15 patients, also had BM and PB samples examined sequentially. RESULTS. Comparing the 45 paired samples concurrently drawn, 16 of 28 BM samples (57.1%) and 4 of 28 PB samples (14.2%) obtained during complete remission (CR) were positive for TH mRNA (P < 0.01), whereas 17 of 17 BM samples (100%) and 14 of 17 PB samples (82.3%) obtained before CR was achieved were positive (not significant). The incidence of TH mRNA positivity was significantly lower in the samples obtained during CR than those obtained before CR was achieved (P < 0.0001 for PB samples, P < 0.01 for BM samples). At the time of PBSC harvesting, the incidence of TH mRNA positivity was lower in PBSC samples (3 of 15, 20%) than in BM samples obtained concurrently (10 of 15, 66.7%; P < 0.03). CONCLUSIONS. These findings show that there is a substantial risk of tumor cell contamination in harvested PBSCs, although its incidence was lower than that in BM samples. We recommend that PBSCs would be better harvested during remission and should be examined for tumor contamination before use as a stem cell source.

UR - http://www.scopus.com/inward/record.url?scp=0030007132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030007132&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19960315)77:6<1214::AID-CNCR31>3.0.CO;2-2

DO - 10.1002/(SICI)1097-0142(19960315)77:6<1214::AID-CNCR31>3.0.CO;2-2

M3 - Article

C2 - 8635146

AN - SCOPUS:0030007132

VL - 77

SP - 1214

EP - 1219

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -